2|0|Public
50|$|<b>Spiraprilat</b> is {{the active}} {{metabolite}} of Spirapril.|$|E
40|$|Spirapril is a carboxyl-bearing ACE inhibitor; it is a prodrug,the active form being <b>spiraprilat</b> [1, 2]. Spirapril shows a {{balanced}} hepatic and renal excretion, which enables once daily treatment even {{in patients with}} impaired renal function [3, 4]. Spirapril also lacks the first dose effect. ACE inhibitors are the drugs of choice {{in the treatment of}} congestive heart fail-ure, because they are able to decrease both cardiovascular and total mortality [5, 6]. The aim of the CASSIS study was to gain experience about the efficacy, safety and tolerability of the drug in the therapy of congestive heart failure. The detailed results were presented elsewhere [7]. In this article we intend to inform about the most important results of the main study as well as the results of the follow-up. Methods CASSIS was a randomized, double blind, placebo- and active...|$|E

